BL-1020 (perphenazine 4-aminobutanoate) is an investigational orally-active antipsychotic for the possible treatment of schizophrenia.

The chemical is an ester of GABA and perphenazine; pharmacologically it acts as a D2 antagonist and GABA agonist.

It has shown pro-cognitive effects in the trials.

[2] It has been introduced by BioLineRx, a biopharmaceutical development company.

This drug article relating to the nervous system is a stub.